Skip to content
Screener

Beta Bionics BBNX Total Revenue

Total Revenue at other companies

Insulet logo
InsuletPODD
$801.7M+23.5%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$254.56M+5.8%
Medtronic logo
MedtronicMDT
$9.81B+9.9%
Embecta Corp. logo
Embecta Corp.EMBC
$271.7M-8.1%
AdaptHealth logo
AdaptHealthAHCO
$819.8M+5.4%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$481M+47.7%

Segments

By product

See full
I Let$12.65M-5.7%
Single Use Products$11.38M+118%

By geography

See full
Non Us$0

Other financials

Income statement

See full
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%
Debt / equity0.0×
Current ratio8.9×-5.8×

Where this comes from

Reported directly by Beta Bionics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net sales$32,013$23,238$59,639$40,877
Cost of sales13,11110,73524,30019,403
Gross profit18,90212,50335,33921,474
Operating expenses:
Research and development10,2408,87320,59616,463
Sales and marketing24,64015,62345,37529,025
General and administrative9,6007,87919,21714,500
Total operating expenses44,48032,37585,18859,988

Item 1. Financial Statements.

FAQ

What is Beta Bionics's total revenue?
Beta Bionics (BBNX) reported total revenue of $32.01M in Q2 2026.
How has Beta Bionics's total revenue changed year-over-year?
Beta Bionics's total revenue increased by 37.8% year-over-year, from $23.24M to $32.01M.
What is the long-term trend for Beta Bionics's total revenue?
Over 2 years (2023 to 2025), Beta Bionics's total revenue has grown at a 189.1% compound annual growth rate (CAGR), from $12M to $100.25M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Beta Bionics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude